Open RFP

TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform RFP

Description: A novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations.

Buyer: Triad National Security (Los Alamos) (Contractor)
Federal · NM, US
Released: Jun 4, 2026
Closes: Dec 3, 2026(81 days left)

Files

Original attachments and procurement documents tied to this bid.

Federal RFP files are for Starbridge customers only.

You can request RFP files from all other buyer types for free on this site.

Key Contacts

Decision makers connected to this RFP from Triad National Security (Los Alamos) (Contractor).

Lisa LloydChief Financial Officer

*******@************

+1 (***) ***-****

Elaine SchuckChief Information Security Officer

*******@************

+1 (***) ***-****

Nathan MoodyDirector, Entrepreneurship for Mission Innovation

*******@************

+1 (***) ***-****

Rachel Byars SchroederDirector of Internal Audit & Ethics

*******@************

+1 (***) ***-****

Similar active RFPs

Adjacent opportunities open for bidding right now.

Triad National Security (Los Alamos) (Contractor)
FederalNM
Posted
Jun 15, 2026
Closes
Dec 15, 2026
TECHNOLOGY LICENSING OPPORTUNITY: Bacterial Lipid Nanodiscs Platform RFP
The bacterial lipid nanodiscs platform developed by llaboratory provides a new way to study entire bacterial membranes in a controlled, nanoscale format derived directly from native lipid extracts. Researchers gain access to membrane components that typically remain difficult to isolate, stabilize or analyze, enabling more accurate evaluation of immunogenic lipids and membrane associated targets. The platform offers a safer alternative to handling live high risk pathogens while preserving the biological context that drives meaningful insights for vaccine design and antimicrobial discovery such as therapeutic antibodies to conserved lipids on bacterial membranes.
Triad National Security (Los Alamos) (Contractor)
FederalNM
Posted
Jun 4, 2026
Closes
Dec 3, 2026
TECHNOLOGY LICENSING OPPORTUNITY: Heat Pipe Reactor Wick and Fill Platform RFP
High-temperature heat pipe reactors by improving the way critical wick structures are manufactured and how heat pipe arrays are filled, sealed, and checked for quality.
Triad National Security (Los Alamos) (Contractor)
FederalNM
Posted
Jun 5, 2026
Closes
Dec 5, 2026
TECHNOLOGY LICENSING OPPORTUNITY: SurfGraphPro RFP
SurfGraphPro, an AI tool, transforms complex protein structures into an easy-to-analyze format that helps researchers quickly identify binding sites, predict molecular interactions and understand protein behavior with greater speed and scalability than traditional approaches. By combining 3D surface graph representations with advanced machine learning, this technology from Los Alamos National Laboratory reduces the computational burden of protein analysis while preserving the structural detail needed for high-value applications in drug discovery, antibody design, pathogen detection and custom protein engineering.
Triad National Security (Los Alamos) (Contractor)
FederalNM
Posted
Jun 17, 2026
Closes
Dec 17, 2026
TECHNOLOGY LICENSING OPPORTUNITY: NanoFET RFP
NanoFiber Engineered Therapeutics Platform (NanoFET) from Laboratory offers pharmaceutical and biodefense organizations a modular, adaptable scaffold for building next-generation immunotherapies. By merging self-assembling peptide nanofibers with interchangeable nanobody and peptide components, the platform enables rapid development of targeted treatments that bridge disease agents directly to the patient’s own immune cells.

See your top accountsScan your site in seconds. Starbridge identifies your ICP and surfaces emerging opportunities from board meetings, job changes, new grants, contract expirations, RFPs, and more.

See your top 10 accounts